pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
Endpoints·Jun 9·1 min read
save

Eli Lilly's 340B claims data deadline passes, sparking potential new dispute

Jun 9, 2026·read at Endpoints ↗RegulatoryNeutral

Eli Lilly set a deadline for hospitals to submit 340B drug‑pricing program claims data under its new policy.

The deadline has now passed, and the company has not indicated what actions it will take next.

Industry observers say the lack of response could spark a fresh dispute over how the 340B program is administered.

The situation highlights ongoing tensions between drug makers and hospitals regarding data transparency and pricing discounts.

source

This writeup was produced by pharmadog from original reporting by Endpoints.

Original headline: “Eli Lilly's claims data deadline may kick off new 340B fight”

read at Endpoints ↗
82 words · retrieved Jun 9
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
LILLY4ELI LILLY CO3

related stories

  • May 6Lilly plans new $4.5B manufacturing investment in IndianaEndpoints
  • May 6Cases and Conversations™: Next-Generation Pathology Advances and Considerations for Precision Care in Non–Small Cell Lung Canceronclive
  • May 6Novo hikes guidance on Wegovy pill’s fast sales startBioPharma Dive
  • May 6STAT+: Novo Nordisk’s less-bad news on its Wegovy pill boosts earnings and share priceSTAT
  • May 4STAT+: French regulator fines Novo and Lilly over weight loss ad campaignsSTAT